- Home
- NECB vs TVRD Comparison
NECB vs TVRD Comparison
Compare NECB & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NECB
- TVRD
- Stock Information
- Founded
- NECB 1934
- TVRD 2017
- Country
- NECB United States
- TVRD United States
- Employees
- NECB N/A
- TVRD N/A
- Industry
- NECB Savings Institutions
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- NECB Finance
- TVRD Health Care
- Exchange
- NECB Nasdaq
- TVRD Nasdaq
- Market Cap
- NECB 282.4M
- TVRD 246.5M
- IPO Year
- NECB N/A
- TVRD N/A
- Fundamental
- Price
- NECB $20.23
- TVRD $5.16
- Analyst Decision
- NECB
- TVRD Buy
- Analyst Count
- NECB 0
- TVRD 7
- Target Price
- NECB N/A
- TVRD $51.67
- AVG Volume (30 Days)
- NECB 49.2K
- TVRD 641.3K
- Earning Date
- NECB 10-23-2025
- TVRD 11-21-2025
- Dividend Yield
- NECB 3.96%
- TVRD N/A
- EPS Growth
- NECB N/A
- TVRD N/A
- EPS
- NECB 3.29
- TVRD N/A
- Revenue
- NECB $103,145,000.00
- TVRD N/A
- Revenue This Year
- NECB $1.90
- TVRD N/A
- Revenue Next Year
- NECB $6.93
- TVRD N/A
- P/E Ratio
- NECB $6.14
- TVRD N/A
- Revenue Growth
- NECB N/A
- TVRD N/A
- 52 Week Low
- NECB $19.41
- TVRD $4.96
- 52 Week High
- NECB $31.72
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- NECB 46.96
- TVRD 20.01
- Support Level
- NECB $20.00
- TVRD $5.65
- Resistance Level
- NECB $20.63
- TVRD $7.23
- Average True Range (ATR)
- NECB 0.59
- TVRD 1.32
- MACD
- NECB 0.05
- TVRD -2.73
- Stochastic Oscillator
- NECB 48.15
- TVRD 0.53
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.